Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-05-10
2011-05-10
Skelding, Zachary (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S154100
Reexamination Certificate
active
07939076
ABSTRACT:
Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD), including Celiac Disease, Crohn's Disease, and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well as polypeptides and small molecules that inhibit the interaction of type 1 interferon with its receptor (IFNAR).
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5516515 (1996-05-01), Vellucci et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5731169 (1998-03-01), Mogensen et al.
patent: 5861258 (1999-01-01), Mogensen et al.
patent: 5886153 (1999-03-01), Mogensen et al.
patent: 5889151 (1999-03-01), Mogensen et al.
patent: 5919453 (1999-07-01), Benoit et al.
patent: 6264981 (2001-07-01), Zhang et al.
patent: 6458932 (2002-10-01), Novick et al.
patent: 6713609 (2004-03-01), Chuntharapai et al.
patent: 6787634 (2004-09-01), Benoit et al.
patent: 7179465 (2007-02-01), Benoit et al.
patent: 7285526 (2007-10-01), Maroun
patent: 7465451 (2008-12-01), Benoit et al.
patent: 2002/0055492 (2002-05-01), Benoit et al.
patent: 2003/0044410 (2003-03-01), Skurkovich et al.
patent: 2003/0166228 (2003-09-01), Chuntharapai et al.
patent: 2004/0067888 (2004-04-01), Tovey et al.
patent: 2005/0152901 (2005-07-01), Pickford et al.
patent: 2005/0208041 (2005-09-01), Cardarelli et al.
patent: 2006/0029601 (2006-02-01), Cardarelli et al.
patent: 2007/0014724 (2007-01-01), Witte et al.
patent: 0369877 (1990-05-01), None
patent: 0563487 (1993-03-01), None
patent: 2 769 505 (1999-04-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/05862 (1991-05-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 93/04699 (1993-03-01), None
patent: WO-93/20187 (1993-10-01), None
patent: WO-94/14467 (1994-07-01), None
patent: WO-95/07716 (1995-03-01), None
patent: WO 95/13808 (1995-05-01), None
patent: WO-97/41229 (1997-11-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 99/39211 (1999-08-01), None
patent: WO 00/24417 (2000-05-01), None
patent: WO 00/53635 (2000-09-01), None
patent: WO 01/09187 (2001-02-01), None
patent: WO 01/14424 (2001-03-01), None
patent: WO 01/54721 (2001-08-01), None
patent: WO-01/55215-AI (2001-08-01), None
patent: WO 02/43478 (2002-06-01), None
patent: WO 02/066649 (2002-08-01), None
patent: WO 2004/093908 (2004-11-01), None
patent: WO 2004/094473 (2004-11-01), None
Huang et al., Pharmacol. Therapeut. 86: 201-215 (2000).
Rampton et al., WJG 4(5): 369-376 (1998).
Cohen, Curr. Gastroenter. Rep. 4: 497-505 (2002).
Stewart et al., Cytokine Growth Factor Rev. Apr. 2003;14(2):139-54, ScienceDirect/Elsevier online publication of Feb. 21, 2003, numbered by the Examiner as pp. 1-31.
Chuntharapai et al., Cytokine. Sep. 7, 2001;15(5):250-60.
Merck Manual of Diagnosis and Therapy, Mark Beers and Robert Berkow, eds., Published by Merck Research Laboratories, 17th ed., 1999, pp. 302-313.
Monteleone et al., Eur J Immunol. Aug. 2001;31(8):2247-55.
Fais et al., J Interferon Res. Oct. 1994;14(5):235-8.
Tanaguchi et al., Curr Opin Immunol. Feb. 2002;14(1):111-6.
MacDonald et al., J Exp Med. Apr. 1, 1988;167(4):1341-9.
Sollid et al., J Exp Med. Jan. 1, 1989;169(1):345-50.
Lewerenz et al., J Mol Biol. Sep. 25, 1998;282(3):585-99.
Musch et al., Aliment Pharmacol Ther. Jul. 2002;16(7):1233-9.
Hanauer et al., Gastroenterology, (1994) vol. 106, No. 4 Suppl., pp. A696.
Davidsen et al., Gastroenterology, (1994) vol. 106, No. 4 Suppl., pp. A670.
Gasche et al., Gastroenterology, (1994) vol. 106, No. 4 Suppl., pp. A685.
Biographical data for ATCC accession No. 65007, printed from the ATCC website on Jun. 4, 2010, pp. 1-2.
GenBank accession No. J03171, Jun. 15, 1990, pp. 1-2.
Benizri, E. et al.: “Prolonged Allograft Survival in Cynomolgus Monkeys Treated with a Monoclonal Antibody to the Human Type I Interferon Receptor and Lowdoses of Cyclosporine,” Journal of Interferon and Cytokine Research, Mary Ann Liebert, Inc., New York, NY, US, vol. 18, 1998, pp. 273-284.
Novick, D. et al.: “The Human Interferon Alpha/Beta Receptor: Characterization and Molecular Cloning” Cell, Cell Press, Cambridge, MA, US, vol. 77, No. 3, May 6, 1994.
Goldman, L. et al.: “Characterization of antihuman IFNAR-1 monoclonal antibodies: Epitope localization and functional analysis,” Journal of Interferon and Cytokine Research, vol. 19, No. 1, Jan. 1999. pp. 15-26.
Novick, D. et al.:“The neutralization of type I IFN biologic actions bu anti-IFNAR-2 monoclonal antibodies is not entirely due to inhibition of Jak-Stat tyrosine phosphorylation,” Journal of Interferon and Cytokine Research, vol. 20, No. 11, Nov. 2000, pp. 971-982.
Colamonici, O. et al.: “Characterization of three monoclonal antibodies that recognize the interferon alpha2 receptor,” Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, US, vol. 87, No. 18, Sep. 1990, pp. 7230-7234.
Constantinescu, S. et al.: “Role of interferon alpha/beta receptor chain 1 in the structure and transmembrane signaling of the interferon alpha/beta receptor complex,” Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, US, vol. 91, No. 20, Sep. 27, 1994, pp. 9602-9606.
Benoit, P. et al.:“A Monoclonal Antibody to Recombinant Human IFN-alpha Receptor Inhibits Biologic Activity of Several Species of Human IFN-alpha, IFN-beta, and IFN-Oniega. Detection of Heterogeneity of the Cellular Type I IFN Receptor,” Journal of Immunology, The Williams and Wilkins Co., Baltimore, US, vol. 150, No. 3, Feb. 1, 1993, pp. 707-716.
Abramovich, C. et al.: “Human IFN-alpha Receptor Detected by Two Monoclonal Antibodies,” Journal of Interferon Research, Mary Ann Liebert, Inc., New York, NY, US, vol. 12, No. suppl 1, Sep. 1, 1992, pp. S217.
Mitoro A, et al., “Exacerbation of ulcerative colitis during alpha-interferon therapy for chronic hepatitis C,”Intern Med. (1993), 32(4):327-31.
Monteleone G, et al., “Role of interferon alpha in promoting T helper cell type 1 responses in the small intestine in coeliac disease,”Gut. (2001), 48(3):425-9.
The New England Journal of Medicine, “Etanercept for Crohn's Disease”, (2004) 350; 8, p. 840 Suzanne Travers and Thomas Kupper.
Sandborn et al., “Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial”, Gastroenterology (2001); 121:1088-1094.
Van den Brande et al., “Infliximab but not Etanercept Induces Apoptosis in Lamina Propria T-Lymphocytes From Patents With Crohn's Disease”, Gastroenterology (2003); 124:1174-1785.
Nash and Florin, “Tumour Necrosis Factor Inhibitors”,Medical Journal of Australia(2005); 183(4): 205-208.
U.S. Appl. No. 12/704,948, filed Feb. 12, 2010, Cardarelli et al.
Aguet et al., “Interferon 5” Ed. I. Gresser p. 1-22,Academic Press, London (1983).
Amin et al., “Innovations in Pharmaceutical Technology,”SamedanLtd, publishers, Jun. 2002.
Arvin AM and Miller JJ 3rd, “Acid labile α-interferon in sera and synovial fluids from patients with juvenile arthritis,”Arthritis Rheum. (1984);27(5):582-5.
Barbas CF et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity,”Proc Natl Acad Sci U S A. (1994);91(9):3809-13.
Blanco P, et al., “Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus,”Science. (2001);294(5546):1540-3.
Branca AA “Bovine spleen, a convenient source for purifying a type I interferon receptor,”J. Interferon Res. 7(1):77-85 (1987).
Brinkmann V, et al., “Interferon α increases the frequency of interferon gamma-producing human CD4+ T cells,”J Exp Med. (1993);178(5):1655-63.
Brown M, et al., “To
Bebbington Christopher R.
King David
Pickford Lesley B.
Yarranton Geoffrey T.
Baker & Botts L.L.P.
Medarex Inc.
Skelding Zachary
LandOfFree
Methods for the therapy of Inflammatory Bowel Disease using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the therapy of Inflammatory Bowel Disease using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the therapy of Inflammatory Bowel Disease using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2660940